High-Dose Influenza Vaccine Offers Superior Protection Against Hospitalization in Older Adults Regardless of Diabetes Status

High-Dose Influenza Vaccine Offers Superior Protection Against Hospitalization in Older Adults Regardless of Diabetes Status

A secondary analysis of the DANFLU-2 trial demonstrates that high-dose influenza vaccines significantly reduce cardiorespiratory and influenza-related hospitalizations in adults aged 65 and older, with consistent benefits observed in patients with diabetes, particularly those with a disease duration exceeding five years.
Digital Storytelling Boosts Pediatric Influenza Vaccination Rates Despite Low Engagement: Insights from a Pilot Randomized Trial

Digital Storytelling Boosts Pediatric Influenza Vaccination Rates Despite Low Engagement: Insights from a Pilot Randomized Trial

A pilot randomized clinical trial reveals that text-based digital stories centered on community voices significantly improved influenza vaccination rates among children in Black communities, even though only 7% of caregivers viewed the narratives, highlighting a potential high-impact intervention for health equity.
Scalable Success: Electronic Patient-Managed Interventions Significantly Drive Benzodiazepine Cessation

Scalable Success: Electronic Patient-Managed Interventions Significantly Drive Benzodiazepine Cessation

The EMPOWER-ED randomized clinical trial demonstrates that an electronic, patient-centered intervention significantly increases the odds of complete benzodiazepine cessation among long-term users, providing a scalable, low-cost solution for health systems to address benzodiazepine dependence without increasing clinician burden.
Adherence to the Planetary Health Diet Index Significantly Lowers MASLD Risk: A Global and Individual-Level Analysis

Adherence to the Planetary Health Diet Index Significantly Lowers MASLD Risk: A Global and Individual-Level Analysis

A comprehensive study integrating global and individual data reveals that adherence to the Planetary Health Diet Index (PHDI) provides significant protection against metabolic dysfunction-associated steatotic liver disease (MASLD), highlighting a sustainable approach to managing the global liver disease epidemic.